Search

Your search keyword '"Belderbos J"' showing total 634 results
Start Over Author "Belderbos J"
634 results on '"Belderbos J"'

103. Dutch Radiotherapy Lung Audit: Results of 2014

Author

Belderbos, J., Troost, E., Berge, M. ten, Walraven, I., Reymen, B., Tissing-Tan, C., Widder, J., Koppe, F., Vonik, E., Coremans, I., Bussink, J., Jaeger, K. de, Zyp, N.V. van, Sharouni, S. el, Knol, H., Peer-Valstar, J., Wel, A. van der, and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
throughput times, waiting times, non-small cell lung cancer, Clinical audit
Published
2015

104. Stereotactic body radiotherapy for central lung tumours: Author reply

Author

Adebahr, S, Collette, S, Shash, E, Lambrecht, M, Le Pechoux, C, Faivre-Finn, C, De Ruysscher, D, Peulen, H, Belderbos, J, Dziadziuszko, R, Fink, C, Guckenberger, M, Hurkmans, C, Nestle, U, University of Zurich, and Nestle, U

Subjects
2741 Radiology, Nuclear Medicine and Imaging, 610 Medicine & health, 10044 Clinic for Radiation Oncology
Published
2015

105. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy.

Author

Wink, K. C. J., Belderbos, J. S. A., Dieleman, E. M. T., Rossi, M., Rasch, C. R. N., Damhuis, R. A. M., Houben, R. M. A., Troost, E. G. C., Wink, K. C. J., Belderbos, J. S. A., Dieleman, E. M. T., Rossi, M., Rasch, C. R. N., Damhuis, R. A. M., Houben, R. M. A., and Troost, E. G. C.

Abstract

BACKGROUND AND PURPOSE: The aim was to investigate whether the use of metformin during concurrent chemoradiotherapy (cCRT) for locally advanced non-small cell lung cancer (NSCLC) improved treatment outcome. MATERIAL AND METHODS: A total of 682 patients were included in this retrospective cohort study (59 metformin users, 623 control patients). All received cCRT in one of three participating radiation oncology departments in the Netherlands between January 2008 and January 2013. Primary endpoint was locoregional recurrence free survival (LRFS), secondary endpoints were overall survival (OS), progression-free survival (PFS) and distant metastasis free survival (DMFS). RESULTS: No significant differences in LRFS or OS were found. Metformin use was associated with an improved DMFS (74% versus 53% at 2years; p=0.01) and PFS (58% versus 37% at 2years and a median PFS of 41months versus 15months; p=0.01). In a multivariate cox-regression analysis, the use of metformin was a statistically significant independent variable for DMFS and PFS (p=0.02 and 0.03). CONCLUSIONS: Metformin use during cCRT is associated with an improved DMFS and PFS for locally advanced NSCLC patients, suggesting that metformin may be a valuable treatment addition in these patients. Evidently, our results merit to be verified in a prospective trial.

Published
2016

117. Stereotactic body radiotherapy for central lung tumours:Author reply

Author

Adebahr, S, primary, Collette, S, additional, Shash, E, additional, Lambrecht, M, additional, Le Pechoux, C, additional, Faivre-Finn, C, additional, De Ruysscher, D, additional, Peulen, H, additional, Belderbos, J, additional, Dziadziuszko, R, additional, Fink, C, additional, Guckenberger, M, additional, Hurkmans, C, additional, and Nestle, U, additional

Published
2015
Full Text
View/download PDF

118. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective

Author

Adebahr, S, primary, Collette, S, additional, Shash, E, additional, Lambrecht, M, additional, Le Pechoux, C, additional, Faivre-Finn, C, additional, De Ruysscher, D, additional, Peulen, H, additional, Belderbos, J, additional, Dziadziuszko, R, additional, Fink, C, additional, Guckenberger, M, additional, Hurkmans, C, additional, and Nestle, U, additional

Published
2015
Full Text
View/download PDF

129. From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions

Author

Koning, C. C. E., Belderbos, J. S. A., and Uitterhoeve, A. L. J.

Subjects
Article Subject
Abstract

Radiotherapy has been the mainstay of the treatment of stage III non-small cell lung cancer (NSCLC) patients. In the early nineties, combined treatment with chemotherapy was introduced. In 1995, a meta-analysis showed improved treatment outcome of the sequential use of radiochemotherapy (RCT) compared to radiotherapy alone, provided cisplatin was part of the chemotherapy course. Concurrent RCT compared to radiotherapy only yielded the same improvements of 4% in the 2-year and 2% in the 5-year overall survival rates. Just recently, two meta-analyses demonstrated that concurrent RCT is definitely superior to sequential RCT in terms of local control and 2-, 3-, and 5-year survival. However, several unanswered questions remain concerning the optimal chemotherapy regimen and radiotherapy doses and techniques in terms of treatment outcome and toxicity profile. Arguments supporting a daily low-dose cisplatin scheme are presented because of comparable radiosensitizing characteristics and favourable side effects. Increasing radiotherapy doses applied according to up-to-date techniques and combinations with new biologicals might lead to further treatment improvements.

Published
2010
Full Text
View/download PDF

131. Perspectieven in de behandeling van het niet-kleincellige longcarcinoom stadium III met radiotherapie en gelijktijdig gegeven laaggedoseerde chemotherapie

Author

Uitterhoeve, A. L. J., Belderbos, J. S. A., van Zandwijk, N., Koning, C. C. E., Cancer Center Amsterdam, and Radiotherapy

Abstract

Patients with a non-small cell lung cancer stage III should preferably be treated with a combination of concomitant radiotherapy and platinum-containing chemotherapy. Concomitant chemoradiation results in improved survival compared to sequential chemoradiation, although this type oftreatment is associated with higher oesophagus toxicity. With concomitant chemoradiation the chemotherapy can be added in several ways to high-dosage radiotherapy, for example in the form of 2 courses of high dose, platinum-containing polychemotherapy once every 3 weeks. Concomitant chemoradiation with just a daily low dose of cisplatin is a good alternative. In view of its low risk of haematological and renal toxicity and ototoxicity and smaller cardiac load this is the therapy of choice and is also highly suitable for elderly patients with comorbidity

Published
2008

134. M031VC (CKTO 2003-04)

Author

Uitterhoeve, A. L. J., Belderbos, J. S. A., and Radiotherapy

Published
2004

141. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer

Author

Uitterhoeve, A. L., Belderbos, J. S., Koolen, M. G., van der Vaart, P. J., Rodrigus, P. T., Benraadt, J., Koning, C. C., González González, D., Bartelink, H., and Other departments

Abstract

The purpose of this work was to study the feasibility of concurrent chemoradiation in patients with inoperable non-small cell lung cancer (NSCLC). 40 patients with inoperable NSCLC were treated with escalating doses of radiotherapy and cisplatin (cDDP). The radiation dose was increased step by step from 60.5 to 66 Gy in daily fractions of 2.75 Gy. Chemotherapy was also increased step by step from 20 to 24 daily doses of cDDP 6 mg/m(2) and given concurrently with radiotherapy. A dose of 40 Gy/2 Gy/20 fractions (fx) was given to the EPTV (elective planning target volume) which included the gross tumour volume with a margin of 2 cm and part of or the entire mediastinum. During each session a boost dose of 0.75 Gy was given simultaneously to the BPTV (boost planning target volume), which encompassed the GTV (gross tumour volume) with a margin of 1 cm, for the first 20 fx, so the total dose to the tumour was 55 Gy. Cisplatin 6 mg/m(2) was given 1 h prior to radiotherapy at each fraction. From then on the dose of radiation to the BPTV and the dose of cDDP were increased step by step. In group I the BPTV was irradiated with two extra fractions of 2.75 Gy to a total dose of 60. 5 Gy without cDDP. In group II the same total dose of 60.5 Gy was given but the last two fractions were combined with cDDP. In group III four extra fractions of 2.75 Gy were given to the BPTV to a total dose of 66 Gy, only two of these fractions combined with cDDP. Finally, in group IV a total dose of 66 Gy was given in 24 fractions, all fractions combined with cDDP. All patients were planned by means of a CT-based conformal treatment planning. The maximal length of the oesophagus receiving >/=60.5 Gy was 11 cm. 40 patients were evaluable for acute and late toxicity and for survival. Acute toxicity grade >/=3 (common toxicity criteria, CTC) was rarely observed; nausea/vomiting in 3 patients (8%), leucopenia in 2 patients (5%), thrombocytopenia in 2 patients (5%), whilst 2 patients (5%) suffered from severe weight loss. Late side-effects (European Organization for Research and Treatment of Cancer/Radiation Therapy Oncology Group, EORTC/RTOG) were: oesophageal toxicity >/=grade 3 in 2 patients (5%) and radiation pneumonitis grades 1 (3%) and 2 (3%) in 1 patient each. Overall actuarial 1- and 2-year survival was 53% and 40%, respectively. The 1- and 2-year local disease-free interval was 65% and 58% respectively. Radiotherapy at a dose of 66 Gy/2.75 Gy/24 fx combined with daily cDDP 6 mg/m(2) given over 5 weeks is feasible and results in a good local disease-free interval and a good survival rate. This treatment schedule is at present being tested as one of the two treatment arms of EORTC phase III study protocol 08972/22973

Published
2000

142. Poor Pulmonary Function is Not Associated with Increased Rates of Toxicity or Decreased Overall Survival After Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer: Results of a Multi-institutional Analysis

Author

Guckenberger, M., Belderbos, J., Hope, A., Kestin, L. L., Werner-Wasik, M., Sonke, J. J., Xiao, Y., Yan, D., Wilbert, J., Grills, I. S., Guckenberger, M., Belderbos, J., Hope, A., Kestin, L. L., Werner-Wasik, M., Sonke, J. J., Xiao, Y., Yan, D., Wilbert, J., and Grills, I. S.

Abstract

Purpose/Objective(s): Stereotactic body radiotherapy (SBRT) is considered as the treatment of choice for stage I non-small cell lung cancer (NSCLC) in medically inoperable patients. It was the purpose of this study to evaluate whether pretreatment pulmonary function is predictive for survival and toxicity after SBRT. American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Published
2010

143. A Multi-national Pooled Analysis of 434 Cases of Stage I Non-small Cell Lung Cancer (NSCLC) Treated with Volumetrically Image-guided Stereotactic Lung Radiotherapy: Results from the Elekta Collaborative Lung Research Group

Author

Grills, I. S., Hope, A. J., Guckenberger, M., Kestin, L. L., Werner-Wasik, M., Yan, D., Sonke, J. J., Bissonnette, J. P., Xiao, Y., Belderbos, J., Grills, I. S., Hope, A. J., Guckenberger, M., Kestin, L. L., Werner-Wasik, M., Yan, D., Sonke, J. J., Bissonnette, J. P., Xiao, Y., and Belderbos, J.

Abstract

Background: Published lung SBRT outcomes/dose response data for inoperable NSCLC come from small phase I-II studies or larger datasets not requiring image-guided radiotherapy (IGRT) or volumetric prescriptions. This entire cohort of SBRT patients had daily online cone-beam CT. American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Published
2010

144. Substantial Dose-response Relationship with Clinical Outcome for Lung Stereotactic Body Radiotherapy (SBRT) Delivered via Online Image Guidance

Author

Kestin, L., Grills, I., Guckenberger, M., Belderbos, J., Hope, A. J., Werner-Wasik, M., Sonke, J. J., Bissonnette, J. P., Xiao, Y., Yan, D., Kestin, L., Grills, I., Guckenberger, M., Belderbos, J., Hope, A. J., Werner-Wasik, M., Sonke, J. J., Bissonnette, J. P., Xiao, Y., and Yan, D.

Abstract

Purpose: To examine potential tumor dose-response relationships with various non-small cell lung cancer (NSCLC) SBRT fractionation regimens delivered with online CT-based image guidance. American Society for Therapeutic Radiation Oncology (ASTRO) 52nd Annual Meeting October 31 - November 4, San Diego, CA

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results